ArticlePloS one2026
ILF3 regulates erythroid differentiation: A single-cell transcriptomic analysis and cellular experiment.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite extensive knowledge of erythropoiesis, the role of interleukin enhancer binding factor 3 (ILF3) in β-thalassemia remains unclear. The aim of this study was to investigate the expression pattern and functional role of ILF3 during erythroid differentiation in β-thalassemia.
methods(1) Single-cell transcriptomic profiles were constructed based on the GSE133181 dataset (3 healthy controls and 3 β-thalassemia patients). The differential expression of ILF3, transcriptional programs of erythroid subsets, pathway activity, and differentiation trajectory were analyzed. (2) ILF3 was knocked out in K562 cells using sgRNA. Cell proliferation was detected by CCK-8 assay, and apoptosis was measured by Annexin V-APC single staining.
results(1) ILF3 was downregulated in the β-thalassemia group, and the proportion of erythroid cells was significantly enriched in ILF3+ cells. (2) ILF3+ erythroid cells highly expressed maturation-related genes and were enriched in cell cycle and metabolic synthesis pathways, while ILF3- cells highly expressed stress-related genes and activated inflammatory stress pathways. (3) Trajectory analysis suggested early arrest of erythroid differentiation in β-thalassemia, with consistently low ILF3 expression throughout the disease group. (4) Knockout of ILF3 promoted apoptosis in K562 cells.
conclusionILF3 is downregulated in β-thalassemia, and its deficiency may contribute to erythroid differentiation arrest and ineffective hematopoiesis by inducing apoptosis and potentially enhancing inflammatory stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.